Pironetin
Based on 1 Customer Validation
Pironetin is an α/β unsaturated lactone isolated from Streptomyces species. Pironetin binds to α-tubulin and is a potent inhibitor of microtubule polymerization, and has cell cycle arrest and antitumor activity.
For research use only. We do not sell to patients.
- Purity: 96.79%
- CAS No.: 151519-02-7
- Formula: C19H32O4
- Molecular Weight:324.45
-
Storage:Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Microtubule[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | GI50 |
22.2 nM
Compound: 1
|
Inhibition of tubulin alpha in human A2780 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Inhibition of tubulin alpha in human A2780 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30693770] |
| A2780 | IC50 |
0.0029 μM
Compound: Pironetin
|
Cytotoxicity against compound-sensitive human A2780 cells after 24 hrs by MTT assay
Cytotoxicity against compound-sensitive human A2780 cells after 24 hrs by MTT assay
|
[PMID: 21396747] |
| A2780 | IC50 |
0.008 μM
Compound: pironetin
|
Cytotoxicity against human A2780 cells after 24 hrs by MTT assay
Cytotoxicity against human A2780 cells after 24 hrs by MTT assay
|
[PMID: 25426924] |
| A2780 | IC50 |
26 nM
Compound: 1
|
Inhibition of tubulin alpha in human A2780 cells assessed as reduction in cell growth
Inhibition of tubulin alpha in human A2780 cells assessed as reduction in cell growth
|
[PMID: 30693770] |
| A2780 ADR | IC50 |
0.003 μM
Compound: Pironetin
|
Cytotoxicity against compound-resistant human A2780AD cells after 24 hrs by MTT assay
Cytotoxicity against compound-resistant human A2780AD cells after 24 hrs by MTT assay
|
[PMID: 21396747] |
| A2780 ADR | IC50 |
0.025 μM
Compound: pironetin
|
Cytotoxicity against human A2780AD cells after 24 hrs by MTT assay
Cytotoxicity against human A2780AD cells after 24 hrs by MTT assay
|
[PMID: 25426924] |
| A549 | GI50 |
7.5 nM
Compound: 1; (-)-PA-48153C
|
Cytotoxicity against human A549 cells assessed as reduction in growth after 4 days by HCS assay
Cytotoxicity against human A549 cells assessed as reduction in growth after 4 days by HCS assay
|
[PMID: 31130264] |
| DC3F | GI50 |
9.5 nM
Compound: 1; (-)-PA-48153C
|
Cytotoxicity against hamster DC-3F cells assessed as reduction in growth after 4 days by HCS assay
Cytotoxicity against hamster DC-3F cells assessed as reduction in growth after 4 days by HCS assay
|
[PMID: 31130264] |
| EL4 | GI50 |
15 nM
Compound: 1; (-)-PA-48153C
|
Cytotoxicity against C57BL/6 mouse EL4 cells assessed as reduction in growth after 3 days
Cytotoxicity against C57BL/6 mouse EL4 cells assessed as reduction in growth after 3 days
|
[PMID: 31130264] |
| HCT-15 | IC50 |
<0.015 μM
Compound: Pironetin
|
Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 30601004] |
| HEK293 | IC50 |
0.017 μM
Compound: Pironetin
|
Cytotoxicity against HEK293 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
|
[PMID: 25240870] |
| HEK293 | IC50 |
0.017 μM
Compound: pironetin
|
Cytotoxicity against human HEK293 cells after 3 days by MTT assay
Cytotoxicity against human HEK293 cells after 3 days by MTT assay
|
[PMID: 25426924] |
| HeLa | GI50 |
30 nM
Compound: 1; (-)-PA-48153C
|
Cytotoxicity against human HeLa cells assessed as reduction in growth
Cytotoxicity against human HeLa cells assessed as reduction in growth
|
[PMID: 31130264] |
| HeLa | IC50 |
0.092 μM
Compound: Pironetin
|
Cytotoxicity against human HeLa cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human HeLa cells after 48 hrs by sulforhodamine B assay
|
[PMID: 30601004] |
| HL-60 | GI50 |
20 nM
Compound: 1; (-)-PA-48153C
|
Cytotoxicity against human HL60 cells assessed as reduction in growth after 24 hrs by MTT assay
Cytotoxicity against human HL60 cells assessed as reduction in growth after 24 hrs by MTT assay
|
[PMID: 31130264] |
| HT-29 | IC50 |
0.0064 μM
Compound: Pironetin
|
Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
|
[PMID: 25240870] |
| HT-29 | IC50 |
0.0064 μM
Compound: pironetin
|
Cytotoxicity against human HT-29 cells after 3 days by MTT assay
Cytotoxicity against human HT-29 cells after 3 days by MTT assay
|
[PMID: 25426924] |
| K562 | GI50 |
17.3 nM
Compound: 1; (-)-PA-48153C
|
Cytotoxicity against human K562 cells assessed as reduction in growth after 4 days by MTT assay
Cytotoxicity against human K562 cells assessed as reduction in growth after 4 days by MTT assay
|
[PMID: 31130264] |
| K562/Adr | GI50 |
16 nM
Compound: 1; (-)-PA-48153C
|
Cytotoxicity against human K562/ADR cells assessed as reduction in growth after 4 days by MTT assay
Cytotoxicity against human K562/ADR cells assessed as reduction in growth after 4 days by MTT assay
|
[PMID: 31130264] |
| MCF7 | GI50 |
5 nM
Compound: 1; (-)-PA-48153C
|
Cytotoxicity against human MCF7 cells assessed as reduction in growth after 3 days by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in growth after 3 days by MTT assay
|
[PMID: 31130264] |
| MCF7 | IC50 |
0.006 μM
Compound: Pironetin
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
|
[PMID: 25240870] |
| MCF7 | IC50 |
0.006 μM
Compound: pironetin
|
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
|
[PMID: 25426924] |
| MCF7 | IC50 |
0.015 μM
Compound: Pironetin
|
Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 30601004] |
| MDA-MB-231 | GI50 |
4.6 nM
Compound: 1; (-)-PA-48153C
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in growth after 4 days by HCS assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in growth after 4 days by HCS assay
|
[PMID: 31130264] |
| NCI-H69 | GI50 |
17.5 nM
Compound: 1; (-)-PA-48153C
|
Cytotoxicity against human H69 cells assessed as reduction in growth after 7 days by MTT assay
Cytotoxicity against human H69 cells assessed as reduction in growth after 7 days by MTT assay
|
[PMID: 31130264] |
| P388 | GI50 |
100 nM
Compound: 1; (-)-PA-48153C
|
Cytotoxicity against mouse P388 cells assessed as reduction in growth after 24 hrs by MTT assay
Cytotoxicity against mouse P388 cells assessed as reduction in growth after 24 hrs by MTT assay
|
[PMID: 31130264] |
| T98G | GI50 |
7.5 nM
Compound: 1; (-)-PA-48153C
|
Cytotoxicity against human T98G cells assessed as reduction in growth after 4 days by MTS assay
Cytotoxicity against human T98G cells assessed as reduction in growth after 4 days by MTS assay
|
[PMID: 31130264] |
Pironetin (20-100 ng/mL; 24 hours; 3Y1 cells) treatment arrests the cell cycle progression at G2/M in 3Y1 cells[1].
Pironetin (1-10000 ng/mL; 3 days; HeLa, A2780 and K-NRK cells) treatment inhibits the cell proliferation. IC50 values against these cell lines are almost 10 ng/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:3Y1 cells
-
Concentration:20 ng/mL, 50 ng/mL, 100 ng/mL
-
Incubation Time:24 hours
-
Result:Arrested the cell cycle progression at G2/M in3Y1 cells.
-
Cell Line:HeLa, A2780 and K-NRK cells
-
Concentration:1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL and 10000 ng/mL
-
Incubation Time:3 days
-
Result:Inhibited the cell proliferation.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female CDF1-SLC mice (10 weeks) injected with P388 murine leukemia cells[1]
-
Dosage:0.78 mg/kg, 1.56 mg/kg, 3.13 mg/kg, 6.25 mg/kg
-
Administration:Intraperitoneal injection; daily; for 5 days
-
Result:Showed a moderate antitumor effect.
Chemical Information
-
CAS No. 151519-02-7
-
Appearance Oil
-
Molecular Weight 324.45
-
Formula C19H32O4
-
Color Colorless to off-white
-
SMILES
O=C1C=C[C@H]([C@H](O1)C[C@H]([C@@H]([C@@H]([C@H](C/C=C/C)C)OC)C)O)CC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kondoh M, et al. Cell cycle arrest and antitumor activity of pironetin and its derivatives. Cancer Lett. 1998 Apr 10;126(1):29-32. [Content Brief]
[2]. Yang J, et al. Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule. ] Nat Commun. 2016 Jun 30;7:12103. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)